ORDER A TEST Log In Contact Us

NEWS

Press Releases

Media Coverage

Additional Partnerships

Filter By
For all media inquiries, please contact media@tempus.com
  • 05/05/2026

    Tempus Reports First Quarter 2026 Results

    CHICAGO, May 5, 2026 — Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine and patient care, today reported financial results for the quarter ended March 31, 2026. Revenue of $348.1 million, up 36.1% year-over-year Diagnostics revenue of $261.1 million, representing 34.7% growth year-over-year, driven by Oncology...

  • 04/29/2026

    Tempus to Host Inaugural Investor Day on May 29, 2026

    Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine, today announced that the company will host an Investor Day on Friday, May 29, 2026. The event will start at 8:00 a.m. CT / 9:00 a.m. ET and will feature Tempus’ leadership team, including, Foun...

  • 04/28/2026

    Tempus Named to TIME’s 10 Most Influential Health and Life Science Companies of 2026

    Tempus AI, Inc. (NASDAQ: TEM), a technology company advancing precision medicine through the practical application of artificial intelligence, today announced it has been named to TIME’s 10 Most Influential Health and Life Science Companies of 2026. This inaugural TIME100 Companies: Industry Leaders list, an expansion of the TIME100 Most Influential Companies issue, recog...

  • 04/23/2026

    Tempus and USC Announce Strategic Collaboration to Accelerate AI-Driven Precision Medicine

    Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine, and the Keck School of Medicine of USC and Keck Medicine of USC, today announced a multi-faceted collaboration aimed at transforming patient care and accelerating research through the power of data and AI. This collaborat...

  • 04/21/2026

    Tempus to Report First Quarter 2026 Financial Results on May 5

    Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine, today announced it will report financial results for the first quarter ended March 31, 2026 on Tuesday, May 5, 2026.  The company will host a conference call and live audio webcast at 4:30 p.m. ET to discuss the results and provide a...

  • 04/15/2026

    Tempus and Predicta Biosciences Announce Collaboration to Expand Life Sciences Access to Ultrasensitive Whole-Genome Sequencing Assay for Hematologic Malignancies and MRD Monitoring

     Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine, and Predicta Biosciences, a precision oncology company developing novel diagnostic solutions for deep molecular characterization of hematologic malignancies with a focus on circulating tumor cells, today announced the commercial expansion of a co-bra...

  • 04/14/2026

    Tempus Announces 31 Abstracts for Presentation at the American Association for Cancer Research Annual Meeting 2026

    Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine, today announced the acceptance of 31 abstracts—including one oral presentation—for the American Association for Cancer Research (AACR) Annual Meeting 2026 taking place April 17–22 in San Diego.  “The research that Tempus is presenting at...

  • 04/13/2026

    Tempus Launches Automated “Active Follow-Up” Service to Support Guideline-Concordant Care

    Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine, today announced the launch of an automated clinical update service designed to support guideline-concordant care by placing patients on an "active follow-up" track. This integrated workflow provides clinicians with ongoing therapy monitoring...

  • 04/09/2026

    Tempus Announces Strategic Collaboration with Gilead to Advance Oncology R&D Through RWE

    Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine, today announced an expanded, multi-year collaboration with Gilead Sciences, Inc. (Nasdaq: GILD) aimed at building and advancing Gilead’s oncology pipeline. To date, Gilead has leveraged Tempus’ extensive repository of de-identified multimodal...

  • 04/08/2026

    Tempus to Present at the 25th Annual Needham Virtual Healthcare Conference

    Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine, will present at the 25th Annual Needham Virtual Healthcare Conference, taking place April 13-16.  Tempus’ Chief Financial Officer, Jim Rogers, will participate in a fireside discussion at the conference on Tuesday, April 14 at 11:45 am...

1 2 3